Both membranous stain intensity and percentage of tumor cells stained are important for CLDN18.2 reporting1
In addition to membranous stain intensity and percentage of tumor cells stained, it is recommended that the biomarker report also include:
- The type of testing method and antibody used
- A description of the status of the sample, such as “positive,” “negative,” or “inconclusive”
- Any relevant notes or observations regarding the sample or results
How to Report CLDN18.2
Kristina A. Matkowskyj, MD, PhD
CLDN18.2 Reporting Example
Developed collaboratively by the CLDN18.2 Key External Expert Committee, consider the following example when integrating CLDN18.2 reporting into your current protocols.
Using the CLDN18.2 Reporting Example
Kristina A. Matkowskyj, MD, PhD
Consistent, integrated reporting of biomarkers can inform clinical decision making that may impact patient care2
Integrated biomarker reporting:
- Gives the HCP the ability to review biomarker test results that inform clinical approach
- Can be used as a tool to help pathologists educate the multidisciplinary team
References: 1. Pellino A, Brignola S, Riello E, et al. Association of CLDN18 protein expression with clinicopathological features and prognosis in advanced gastric and gastroesophageal junction adenocarcinomas. J Pers Med (Epub) 10-26-2021. 2. Warner JL, Jain SK, Levy MA. Integrating cancer genomic data into electronic health records. Genome Medicine (Epub) 10-26-2016.